31.01.20: Not intended for U.S. and UK Media

Bayer receives positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancerCHMP opinion is based on Phase III ARAMIS trial data evaluating the efficacy and safety of darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADT / Final decision from the European Commission is anticipated within the coming monthsmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news